Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Core Insights - The company Janux has reported what it describes as 'positive trial data' for its innovative treatment targeting patients with late-stage prostate cancer [1] Group 1 - The trial data indicates promising results for the treatment, suggesting potential efficacy in a challenging patient population [1]